Skip to Content
MilliporeSigma
All Photos(3)

Key Documents

SAB4200104

Sigma-Aldrich

Anti-Gigaxonin (N-terminal) antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody

Synonym(s):

Anti-GAN, Anti-GAN1, Anti-Giant axonal neuropathy 1, Anti-KLHL16 (kelch-like protein 16)

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen ~70 kDa

species reactivity

mouse, human, rat

concentration

~1.5 mg/mL

technique(s)

immunoprecipitation (IP): 15-30 μg using rat brain extracts (S1 fraction)
indirect immunofluorescence: 10-20 μg/mL using HeLa cells expressing human gigaxonin
western blot: 1-2 μg/mL using mouse brain extracts (S1 fraction), and 1.5-3 μg/mL using SH-SY5Y cell lysates
western blot: 1.5-3 μg/mL using SH-SY5Y cell lysates

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... GAN(8139)
mouse ... Gan(209239)
rat ... Gan(307893)

General description

Gigaxonin (GAN) is encoded by the gene mapped to human chromosome 16q23.2. The encoded protein is characterized with an N-terminal BTB (for broad-complex, ramtrack and bric a brac) domain followed by a six kelch repeats, which are predicted to adopt a β-propeller shape.8

Application

Anti-Gigaxonin (N-terminal) antibody produced in rabbit has been used in immunofluorescence and immunoblotting assay.[1]

Biochem/physiol Actions

Gigaxonin (GAN) acts as a key regulator of intermediate filaments (IFs) and the microtubule-associated protein 1B (MAP1B) light chain degradation, which is required for neuronal survival. GAN contributes to neurofilament architecture. Additionally, it also influences the ubiquitination and degradation of some proteins. Mutation in the gene is associated with the development of giant axonal neuropathy.[1]

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Novel homozygous missense mutation in GAN associated with Charcot-Marie-Tooth disease type 2 in a large consanguineous family from Israel
Aharoni S
BMC Medical Genetics, 17, 82-82 (2016)
Electronic medical records and genomics (eMERGE) network exploration in cataract: Several new potential susceptibility loci
Ritchie MD
Molecular Vision, 20, 1281-1295 (2014)
The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy
Bomont P
Nature Genetics, 26, 370-374 (2000)
Rachel M Bailey et al.
Molecular therapy. Methods & clinical development, 9, 160-171 (2018-05-17)
An NIH-sponsored phase I clinical trial is underway to test a potential treatment for giant axonal neuropathy (GAN) using viral-mediated GAN gene replacement (https://clinicaltrials.gov/ct2/show/NCT02362438). This trial marks the first instance of intrathecal (IT) adeno-associated viral (AAV) gene transfer in humans.
Po-Han Chen et al.
JCI insight, 5(1) (2020-01-17)
Gigaxonin (also known as KLHL16) is an E3 ligase adaptor protein that promotes the ubiquitination and degradation of intermediate filament (IF) proteins. Mutations in human gigaxonin cause the fatal neurodegenerative disease giant axonal neuropathy (GAN), in which IF proteins accumulate

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service